R-2cda and Prolongation of Therapy With Rituximab Alone in Chronic Lymphocytic Leukaemia and Small Lymphocytic Lymphoma

This study has been terminated.
(low rate in patient accrual)
Information provided by (Responsible Party):
European Institute of Oncology
ClinicalTrials.gov Identifier:
First received: June 15, 2011
Last updated: September 28, 2015
Last verified: September 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Estimated Study Completion Date: December 2017
  Estimated Primary Completion Date: August 2017 (Final data collection date for primary outcome measure)